Key statistics
On Monday, Connect Biopharma Holdings Ltd (CNTB:NMQ) closed at 0.98, 92.16% above the 52 week low of 0.51 set on Apr 04, 2025.
52-week range
Open | 0.9803 |
---|---|
High | 1.06 |
Low | 0.98 |
Bid | 0.9703 |
Offer | 1.07 |
Previous close | 1.00 |
Average volume | 80.93k |
---|---|
Shares outstanding | 55.56m |
Free float | 32.51m |
P/E (TTM) | -- |
Market cap | 55.56m USD |
EPS (TTM) | -0.3109 USD |
Data delayed at least 15 minutes, as of Jun 30 2025 20:56 BST.
More ▼
- Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
- Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
- Connect Biopharma to Present at Two Upcoming Investor Conferences in June
- Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference
- Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update
- Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD
- Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
- Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference
- Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart
- Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma
More ▼